Search results
Showing 7351 to 7365 of 7708 results
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)
This guidance has been updated and replaced by NICE technology appraisal guidance 988.
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]
In development [GID-TA11580] Expected publication date: TBC
The MAGEC system for spinal lengthening in children with scoliosis (MTG18)
August 2024: Following the lifting on the UK suspension of MAGEC system (modified MAGEC X system), NICE's prioritisation board will be reviewing the guidance that was withdrawn in April 2020. We will update this page once a decision is made.
NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection because there is published evidence that shows it offers no clinical benefits over standard care (clean catch method).
In development [GID-MT538] Expected publication date: TBC
This guidance has been updated and replaced by NICE interventional procedures guidance 793.
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]
Discontinued [GID-TA11522]
Common mental health problems: identification and pathways to care (CG123)
We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on:
Intrapartum care for healthy women and babies - rectal examination after delivery
Discontinued [GID-NG10395]
Violence and aggression: short-term management in mental health, health and community settings
Discontinued [GID-NG10397]
June 2023: We are aware that the International Journal of Gynecology and Obstetrics has retracted a 2016 paper, which was used in committee decision making for this topic (IPG744). As the evidence base has now changed, it is returning to committee for re-discussion, see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. Once the schedule for this has been confirmed, it will be communicated to stakeholders and published on the NICE website. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).
September 2024: We have withdrawn this guidance. This is because the main evidence that the guidance was based on has been retracted by the journal. New NICE interventional procedures guidance is in development and the expected publication date is April 2025. Please see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
This guidance has been updated and replaced by NICE technology appraisal guidance TA802.
This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.
In development [GID-TA11104] Expected publication date: TBC